PIH84 Practical Considerations for Estimating Sample Size and Study Duration in Pregnancy Exposure Registries  by Covington, D. et al.
ment, cystic fibrosis, hematologic-metabolic syndromes, overweight, and psycho-
social problems. A comparison between adult and pediatric HTAs was undertaken
for 222 reports published in 2007-2008. RESULTS:Whereas the most common con-
ditions studied in adults were cancer, cardiovascular disorders and rheumatologi-
cal disorders, diseases most commonly studied in children were asthma, autism,
cystic fibrosis and diabetes. In addition to differences between adults and children
related to measurement, analysis and the availability of evidence, the social, legal
and ethical issues that influence decision-making are unique for children due to
their vulnerability and lack of autonomy. CONCLUSIONS: As HTA increasingly
becomes the basis for decision-making, the challenges in applying HTA to child
health must be considered to ensure equity in health care policy.
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PRACTICAL CONSIDERATIONS FOR ESTIMATING SAMPLE SIZE AND STUDY
DURATION IN PREGNANCY EXPOSURE REGISTRIES
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PPD, Wilmington, NC, USA
OBJECTIVES: Pregnancy exposure registries are important tools to evaluate drug
safety in pregnancy. Because pregnancy registries are unique, they present chal-
lenges in estimating critical factors impacting sample size and study duration,
including accrual, retention, and live birth (LB) rates. The objective of this study is
to examine these 3 factors in ongoing pregnancy registries and estimate impact on
sample size and enrollment duration. METHODS: We examined published data
from pregnancy registries identified through the internet and literature searches.
Of the 58 pregnancy registries identified, 21 (36%) had published data available. Of
the 21, only 18 published sufficient detail to allow calculation of LB, retention, and
accrual rates. RESULTS: The average duration for registries with published data
available was 8.8 years compared to 2.7 years for registries with no published data.
Themedian LB rate for single-drug registries was 88% (range: 62-95%), which is 45%
higher than the population rate. The median retention rate was 73% (range: 37%-
99%). The median accrual per year was 81.9 (range: 5.3-296). Using the median
rates, 422 pregnancies would need to be enrolled over 5 years to achieve sufficient
power to rule out a twofold increase in risk of birth defects. The rates varied from
a low of 320 pregnancies enrolled over 1.1 years to a high of 570 pregnancies en-
rolled over 100 years. Factors impacting the variability of rates included drug indi-
cation, patient population, design, data source, location, and recruitment and re-
tention activities. CONCLUSIONS: The LB rate was the least volatile of the factors
examined and the accrual ratewas themost volatile. Using the observed rates from
other pregnancy registries as a guide may aid in determining sample size and
enrollment timelines, but these rates are highly variable. Careful consideration
should also be given to factors that could impact these rates.
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THE DISABILITY AND QOL WITH THE ELDERLY
Tazaki M, Yamaguchi T
TOHO University, Tokyo, Japan
OBJECTIVES: The aims of this research were 1) to develop the Japanese version of
the World Health Organization Disability Assessment Schedule II (WHODAS II),
which was created to evaluate levels of disabilities based on the International
Classification of Functioning; 2) to evaluate the psychometric properties of the
instrument to check its validity and reliability; 3) to evaluate its applicability to the
elderlywith andwithout disabilities. In this study, a proxy-administered version of
36-items, an interviewer-administered version of 36-items, and the WHO Quality
of Life (QOL) were delivered.METHODS: At first, the preliminary Japanese version
of the WHODAS II was produced after incorporating feedback from a qualitative
study. Then, a preliminary study was conducted with 45 elderly people over 65
years old with various disabilities at two nursing homes in Tokyo (interviewer
administered) and with 30 professional caregivers at the homes (proxy
administered). RESULTS: The number of participants in the interview version of
the assessment was 45 (male 10: female 35), with a mean age of 80.7 (SD 7.3). The
mean age of the elderly who was cared for by those professional care givers who
answered the proxy versionwas 86.1(SD 6.8). The globalWHODAS IImean score for
the proxy-administered group was 100.5 (SD  31.0), and for the interviewer-ad-
ministered group was 58.5 (SD  19.8). The recommended standard Cronbach’s
alpha coefficient for each domain of the WHODAS II was achieved. For the inter-
viewer-administered group, there was a moderately strong, negative correlation
between the QOL score and theWHODAS score (r -0.62, P 0.01). CONCLUSIONS:
It was found that the Japanese version of the WHODAS II has sufficient reliability,
validity, and applicability for use with elderly with various disabilities, and it was
also found that the more severe the disability, the lower the QOL.
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ADVANCED DISEASE IN OVARIAN CANCER: CLINICAL AND ECONOMIC
OUTCOMES WITHIN HOSPITAL INPATIENT SETTINGS
Tate WR, Skrepnek GH, Alberts DS
The University of Arizona, Tucson, AZ, USA
OBJECTIVES: To assess the characteristics of inpatient mortality and charges as-
sociated with advanced disease in ovarian cancer in the United States from
2005-2009. METHODS: Nationally-representative hospital discharge records from
Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utiliza-
tion Project (H-CUP) Nationwide Inpatient Sample (NIS) from 2005-2009 were used
in this retrospective cohort analysis. Cases18 years of agewith advanced ovarian
cancer were selected. Variables analyzed included sites of metastases, patient de-
mographics, hospital characteristics, lengths of stay, primary payer, and Elix-
hauser comorbidity risk-adjustment. Outcomes of mortality and charges were as-
sessed via multivariate logistic and gamma regression, respectively, yielding odds
ratios (OR) or exponentiated beta coefficients (exp(b)). RESULTS: Overall, 352,319
inpatient ovarian cancer cases were observed from 2005-2009, with an inpatient
mortality rate of 5.3% and a national bill of $13.1 billion. Advanced disease repre-
sented 50.5% of cases, averaging 64.1 (13.4) years of age, an inpatient mortality
rate of 7.2%, and average charges of $46,123 (60,396) or 61.1% of the national bill.
The most commonmetastatic sites were gastrointestinal (60.5%), lung/respiratory
(15.4%), liver/digestive organs (18.4%), lymph (11.9%), and genitourinary (4.4%).
Multivariate analyses indicated significantly (p0.05) higher odds of inpatientmor-
tality with metastases to the liver/digestive organs (OR1.28), lung/respiratory
tract (OR1.66), central nervous system (OR1.62), and kidney (OR1.84). Other
key comorbidities associated with increased inpatient mortality included heart
failure, coagulopathy, liver disease, fluid/electrolyte disorders, neurological disor-
ders, pulmonary circulation disorders, renal failure, and weight loss. Significantly
higher inpatient charges were found with metastases to the skin (exp(b)1.13),
liver/digestive organs (exp(b)1.03), gastrointestinal tract (exp(b)1.25), lymph
nodes (exp(b)1.23), and genitourinary system (exp(b)1.21). CONCLUSIONS: Ad-
vanced disease is found in approximately half of inpatient ovarian cancer cases,
incurring a large burden of illness. The increased understanding ofmetastatic sites
and complications remains imperative to improving treatment and patient out-
comes.
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DEPRESSION TREATMENT IN INDIVIDUALS WITH PHYSICAL ILLNESSES: A
COMPARISON BETWEEN CANCER AND CARDIO-METABOLIC CONDITIONS
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OBJECTIVES: Similar challenges are encountered in management of depression
among individuals with cancer and cardio-metabolic conditions; with presence of
high prevalence of diagnosed depression, negative impact of depression on health
outcomes, and competing demands in clinical care encounters, in both the condi-
tions. Additionally, there has been a lack of robust evidence from clinical trials on
the effectiveness of depression treatment on physical illness outcomes in both
cancer and cardio-metabolic conditions. Thus the objectives of this study were to
compare depression treatment rates among individuals with self-reported depres-
sion and cancer or cardio-metabolic conditions, and to examine the association
between depression treatment and presence of cancer diagnosis after controlling
for demographic, socio-economic, access to care, health status, and lifestyle
characteristics.METHODS: The study used a retrospective cross-sectional design.
Data from multiple years of the Medical Expenditure Panel Survey (MEPS), a na-
tionally representative household survey on healthcare utilization and expendi-
tures was used. Study sample consisted of adults aged 21 or older with self-re-
ported depression and cancer (N  528), or self-reported depression and diabetes,
heart disease or hypertension (N  1643). Depression treatment comprised of any
use of antidepressants and/or any use of mental health counseling services.
RESULTS:Treatment rates for depressionwere 78.0% and 81.7% among individuals
with cancer and cardio-metabolic conditions, respectively. After controlling for
demographic- and socio-economic characteristics, access to care, health status,
lifestyle risk factors, and number of physician visits; individuals with cancer were
less likely to report treatment for depression (AOR 0.67; 95% Confidence Interval
((0.49, 0.92), p  0.01) compared to individuals with cardio-metabolic conditions.
CONCLUSIONS: Our findings suggest that presence of cancer may be associated
with a lower likelihood of receiving depression treatment, perhaps due to cancer
being a clinically dominant condition.
PCN3
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CANCER DIAGNOSIS AMONG MEN IN FLORIDA
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OBJECTIVES:Comorbidity impacts the treatment options and prognosis of prostate
cancer. This study examined association of major types of comorbidity with late-
stage prostate cancer in Florida.METHODS: The studywas a retrospective analysis
of Florida Cancer Registry data. A total of 60,497 prostate cancer cases diagnosed
between 2001-2007 were included. Individual-level data included demographics,
primary health insurance payer and tumor stage at diagnosis. Census-tract level
data included socioeconomic status extracted from Census 2000 and linked to
individual cancer data. County-level provider-to-case ratio was computed based
on data files provided by the Florida Department of Health. Comorbidity was com-
puted following Elixhauser Index. Multi-level logistic regressionwas used to exam-
ine associations of these factors with late-stage prostate cancer diagnosis.
RESULTS: Among individual level factors, late-stage diagnosis was significantly
and independently associated with being black, unmarried, current smoker, unin-
sured, and presence of comorbidities. No associationwas found between late-stage
diagnosis and year of diagnosis except for 2006. People with public insurance and
diagnosed in hospitals were associated with lower likelihood of late-stage diagno-
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